An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus

The aim of the project, carried out within the Polish Society for Pharmacoeconomics (PTFE), was to estimate the potential costs of treatment of the side effects which (theoretically) may occur as a result of treatments for the selected diseases. This paper deals solely with dermatology related event...

Full description

Bibliographic Details
Main Authors: Szkultecka-Debek Monika, Drozd Mariola, Kiepurska Nina, Janowska Agnieszka, Paprzycki Piotr, Paluchowska Beata
Format: Article
Language:English
Published: Sciendo 2014-09-01
Series:Current Issues in Pharmacy and Medical Sciences
Subjects:
Online Access:http://www.degruyter.com/view/j/cipms.2014.27.issue-3/cipms-2015-0012/cipms-2015-0012.xml?format=INT
_version_ 1818197248150863872
author Szkultecka-Debek Monika
Drozd Mariola
Kiepurska Nina
Janowska Agnieszka
Paprzycki Piotr
Paluchowska Beata
author_facet Szkultecka-Debek Monika
Drozd Mariola
Kiepurska Nina
Janowska Agnieszka
Paprzycki Piotr
Paluchowska Beata
author_sort Szkultecka-Debek Monika
collection DOAJ
description The aim of the project, carried out within the Polish Society for Pharmacoeconomics (PTFE), was to estimate the potential costs of treatment of the side effects which (theoretically) may occur as a result of treatments for the selected diseases. This paper deals solely with dermatology related events. Herein, several Drug Programs financed by the National Health Fund in Poland, in 2012, were analyzed. The adverse events were selected based on the Summary of Product Characteristics of the chosen products. We focused the project on those potential adverse events which were defined in SPC as frequent and very frequent. The results are presented according to their therapeutic areas, and in this paper, the focus is upon that which is related to dermatology. The events described as ‘very common’ had an incidence of ≥ 1/10, and that which is ‘common’ - ≥ 1/100, <1 /10. In order to identify the resources used, we, with the engagement of clinical experts, performed a survey. In our work, we employed only the total direct costs incurred by the public payer, based on valid individual cost data in February 2014. Moreover, we calculated the total spending from the public payer’s perspective, as well as the patient’s perspective, and the percentage of each component of the total cost in detail. The paper, thus, informs the reader of the estimated costs of treatment of side effects related to the dermatologic symptoms and reactions. Based on our work, we can state that the treatment of skin adverse drug reactions generates a significant cost - one incurred by both the public payer and the patient.
first_indexed 2024-12-12T01:46:57Z
format Article
id doaj.art-b0526619875a40f99d8fd46301944ce4
institution Directory Open Access Journal
issn 2084-980X
2300-6676
language English
last_indexed 2024-12-12T01:46:57Z
publishDate 2014-09-01
publisher Sciendo
record_format Article
series Current Issues in Pharmacy and Medical Sciences
spelling doaj.art-b0526619875a40f99d8fd46301944ce42022-12-22T00:42:34ZengSciendoCurrent Issues in Pharmacy and Medical Sciences2084-980X2300-66762014-09-0127318318610.1515/cipms-2015-0012cipms-2015-0012An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focusSzkultecka-Debek Monika0Drozd Mariola1Kiepurska Nina2Janowska Agnieszka3Paprzycki Piotr4Paluchowska Beata5Dermatology, Military Institute of Medicine, 128 Szaserow, 04-141 Warsaw, PolandDepartment of Applied Pharmacy, Medical University of Lublin, PolandDermatology, Military Institute of Medicine, 128 Szaserow, 04-141 Warsaw, PolandDepartment of Functional Research, Institute of Rural Health in Lublin, PolandDepartment of Functional Research, Institute of Rural Health in Lublin, PolandDermatology, Military Institute of Medicine, 128 Szaserow, 04-141 Warsaw, PolandThe aim of the project, carried out within the Polish Society for Pharmacoeconomics (PTFE), was to estimate the potential costs of treatment of the side effects which (theoretically) may occur as a result of treatments for the selected diseases. This paper deals solely with dermatology related events. Herein, several Drug Programs financed by the National Health Fund in Poland, in 2012, were analyzed. The adverse events were selected based on the Summary of Product Characteristics of the chosen products. We focused the project on those potential adverse events which were defined in SPC as frequent and very frequent. The results are presented according to their therapeutic areas, and in this paper, the focus is upon that which is related to dermatology. The events described as ‘very common’ had an incidence of ≥ 1/10, and that which is ‘common’ - ≥ 1/100, <1 /10. In order to identify the resources used, we, with the engagement of clinical experts, performed a survey. In our work, we employed only the total direct costs incurred by the public payer, based on valid individual cost data in February 2014. Moreover, we calculated the total spending from the public payer’s perspective, as well as the patient’s perspective, and the percentage of each component of the total cost in detail. The paper, thus, informs the reader of the estimated costs of treatment of side effects related to the dermatologic symptoms and reactions. Based on our work, we can state that the treatment of skin adverse drug reactions generates a significant cost - one incurred by both the public payer and the patient.http://www.degruyter.com/view/j/cipms.2014.27.issue-3/cipms-2015-0012/cipms-2015-0012.xml?format=INTthe cost treatmentadverse eventsdermatology
spellingShingle Szkultecka-Debek Monika
Drozd Mariola
Kiepurska Nina
Janowska Agnieszka
Paprzycki Piotr
Paluchowska Beata
An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus
Current Issues in Pharmacy and Medical Sciences
the cost treatment
adverse events
dermatology
title An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus
title_full An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus
title_fullStr An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus
title_full_unstemmed An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus
title_short An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus
title_sort adverse events potential costs analysis based on drug programs in poland dermatology focus
topic the cost treatment
adverse events
dermatology
url http://www.degruyter.com/view/j/cipms.2014.27.issue-3/cipms-2015-0012/cipms-2015-0012.xml?format=INT
work_keys_str_mv AT szkulteckadebekmonika anadverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT drozdmariola anadverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT kiepurskanina anadverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT janowskaagnieszka anadverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT paprzyckipiotr anadverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT paluchowskabeata anadverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT szkulteckadebekmonika adverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT drozdmariola adverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT kiepurskanina adverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT janowskaagnieszka adverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT paprzyckipiotr adverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus
AT paluchowskabeata adverseeventspotentialcostsanalysisbasedondrugprogramsinpolanddermatologyfocus